

Summary of Consolidated Financial Results (For the First Quarter ended June 30, 2025) [Under Japanese GAAP]

July 31, 2025
Tokyo Stock Exchange

Company name: KYORIN Pharmaceutical Co., Ltd.

Code number: 4569

Web site: <https://www.kyorin-pharm.co.jp/>

Representative : Yutaka Ogihara, Representative Director, President and Chief Executive Officer

Contact: Sakurou Banba, Director, Finance & Accounting

TEL (03) 6374-9704

Scheduled date to commence dividend payments: –

Preparation of supplementary material on financial results: Yes

Holding of financial results briefing: None

(Amounts rounded down to the nearest million yen)

1. Consolidated results for the three months ended June 30, 2025 (from April 1, 2025 to June 30, 2025)

(1) Consolidated operating results

(Percentage changes relative to previous corresponding period)

	Net sales		Operating profit		Ordinary profit		Profit attributable to owners of parent	
	Million yen	%	Million yen	%	Million yen	%	Million yen	%
Three months ended June 30, 2025	30,229	6.4	2,368	106.0	2,624	85.1	2,100	137.1
June 30, 2024	28,419	2.0	1,150	32.0	1,417	32.0	885	12.4

(Note) Comprehensive income: For the three months ended June 30, 2025: 2,020 million yen (72.2%),

For the three months ended June 30, 2024: 1,173 million yen (– 7.2%)

	Earnings per share (Basic)	Earnings per share (Diluted)
Three months ended June 30, 2025	Yen 36.57	Yen —
June 30, 2024	15.42	—

(2) Consolidated financial position

	Total assets	Net assets	Equity ratio
	Million yen	Million yen	%
As of June 30, 2025	190,569	136,153	71.4
March 31, 2025	193,618	136,285	70.4

(Note) Equity: For the three months ended June 30, 2025: 136,153 million yen,

For the fiscal year ended March 31, 2025: 136,285 million yen

2. Dividends

	Annual dividends per share				
(Record date)	First quarter-end	Second quarter-end	Third quarter-end	Fiscal year-end	Total
	Yen	Yen	Yen	Yen	Yen
Fiscal year ended March 31, 2025	—	20.00	—	37.00	57.00
Fiscal year ending March 31, 2026	—				
Fiscal year ending March 31, 2026 (Forecast)		20.00	—	37.00	57.00

(Note) Revisions to the dividend forecast in the current quarter: None

3. Forecast of consolidated for the year ending March 31, 2026 (from April 1, 2025 to March 31, 2026)

(Percentage changes relative to previous corresponding period)

	Net sales		Operating profit		Ordinary profit		Profit attributable to owners of parent		Earnings per share
	Million yen	%	Million yen	%	Million yen	%	Million yen	%	Yen
First half	57,400	4.1	1,700	9.7	1,800	– 12.2	1,400	11.5	24.37
Full year	127,000	– 2.4	6,100	– 51.5	6,300	– 52.3	4,800	– 47.2	83.55

(Note) Revisions to the dividend forecast in the current quarter: None

4. Other

(1) Changes in significant subsidiaries during the period (Change in specified subsidiaries resulting in the scope of consolidation): None

Newly included: None, Excluded: None

(2) Adoption of accounting treatment specific to the preparation of quarterly financial statements : Yes

(3) Changes in accounting policies, changes in accounting estimates and restatements

(i) Changes in accounting policies due to revisions to accounting standards and other regulations: None

(ii) Changes in accounting policies due to other than (i) : None

(iii) Changes in accounting estimates : None

(iv) Restatements : None

(4) Number of shares issued (common stock)

(i) Number of issued shares at the end of the period (including treasury shares)

As of June 30, 2025: 59,945,641 shares,

Fiscal year ended March 31, 2025: 64,607,936 shares

(ii) Number of treasury shares at the end of the period

As of June 30, 2025: 2,496,792 shares,

Fiscal year ended March 31, 2025: 7,159,087 shares

(iii) Averaged number of shares of during the period

As of June 30, 2025: 57,448,849 shares,

As of June 30, 2024: 57,448,675 shares

* This quarterly financial report is not subject to audit procedures by Certified Public Accountants or audit firm.

* Explanations about the appropriate use of the business forecasts and other noteworthy points.

These forecast performance figures are based on information currently available to the Company and may include uncertain factors or risk that affect our future performance. Accordingly, actual business results may materially differ from the forecasted figures due to various factors in the future.

(Methods for obtaining supplementary materials and content of financial results disclosure)

Supplementary materials will be made available on the Company's website in conjunction with the Summary of Consolidated Financial Results.